Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
Conditions
Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Queen Elizabeth Hospital, Birmingham, United Kingdom
Contact: Principal Investigator (Yuk-Ting Ma)Addenbrooke's Hospital, Cambridge, United Kingdom
Contact: Study coordinator (Bristi Basu)Western General Hospital, Edinburgh, United Kingdom
Contact: Principal Investigator (Alan Christie)Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Contact: Principal Investigator (Jeff Evans)St James's Hospital, Leeds, United Kingdom
Contact: Principal Investigator (Daniel Swinson)Clatterbridge Cancer Centre, Liverpool, United Kingdom
Contact: Principal Investigator (Daniel Palmer)Hammersmith Hospital, London, United Kingdom
Contact: Principal Investigator (Rohini Sharma)King's College Hospital, London, United Kingdom
Contact: Study coordinator (Paul Ross)Royal Free Hospital, London, United Kingdom
Contact: Principal Investigator (Tim Meyer)The Christie NHS Foundation Trust, Manchester, United Kingdom
Contact: Principal Investigator (Richard Hubner)Freeman Hospital, Newcastle upon Tyne, United Kingdom
Contact: Principal Investigator (Sanjay Pandanaboyana)
Study leads
Tim Meyer, BSc MBBS PhD FRCP
Principal Investigator
University College, London